-- 根據週一提交給香港交易所的文件顯示，上海復宏漢霖生物技術有限公司（HKG:2696）已獲得日本藥品和醫療器材管理局的默示批准，將在日本進行注射用HLX43的II/III期臨床試驗。 該藥物正在接受單藥治療或與匹莫妥單抗HLX07聯合治療的臨床試驗，並與多西他賽進行比較，用於治療晚期鱗狀非小細胞肺癌。 文件稱，一旦滿足相關條件，公司將啟動試驗。
Related Articles
Mining & Metals
Panoro Minerals Announcing Brokered LIFE Offering for Gross Proceeds of up to $20M
$PML.V
Research
Raymond James Upgrades Acadia Healthcare to Strong Buy From Outperform, Adjusts Price Target to $39 From $25
Acadia Healthcare Company (ACHC) has an average rating of overweight and mean price target of $28.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ACHC
Research
Cantor Fitzgerald Upgrades GlobalFoundries to Overweight From Neutral, Adjusts Price Target to $80 From $50
GlobalFoundries (GFS) has an average rating of overweight and mean price target of $54.68, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$GFS